BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Y, Miller CA, Shea LK, Jiang X, Guzman MA, Chandler RJ, Ramakrishnan SM, Smith SN, Venditti CP, Vogler CA, Ory DS, Ley TJ, Sands MS. Enhanced Efficacy and Increased Long-Term Toxicity of CNS-Directed, AAV-Based Combination Therapy for Krabbe Disease. Mol Ther 2021;29:691-701. [PMID: 33388420 DOI: 10.1016/j.ymthe.2020.12.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Sabatino DE, Bushman FD, Chandler RJ, Crystal RG, Davidson BL, Dolmetsch R, Eggan KC, Gao G, Gil-Farina I, Kay MA, McCarty DM, Montini E, Ndu A, Yuan J; American Society of Gene and Cell Therapy (ASGCT) Working Group on AAV Integration. Evaluating the state of the science for adeno-associated virus integration: An integrated perspective. Mol Ther 2022:S1525-0016(22)00364-1. [PMID: 35690906 DOI: 10.1016/j.ymthe.2022.06.004] [Reference Citation Analysis]
2 Davé UP, Cornetta K. AAV Joins the Rank of Genotoxic Vectors. Mol Ther 2021;29:418-9. [PMID: 33472035 DOI: 10.1016/j.ymthe.2021.01.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
3 Feltri ML, Weinstock NI, Favret J, Dhimal N, Wrabetz L, Shin D. Mechanisms of demyelination and neurodegeneration in globoid cell leukodystrophy. Glia 2021;69:2309-31. [PMID: 33851745 DOI: 10.1002/glia.24008] [Reference Citation Analysis]
4 Hordeaux J, Jeffrey BA, Jian J, Choudhury GR, Michalson K, Mitchell TW, Buza EL, Chichester J, Dyer C, Bagel J, Vite CH, Bradbury AM, Wilson JM. Efficacy and Safety of a Krabbe Disease Gene Therapy. Hum Gene Ther 2022. [PMID: 35333110 DOI: 10.1089/hum.2021.245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Del Grosso A, Parlanti G, Angella L, Giordano N, Tonazzini I, Ottalagana E, Carpi S, Pellegrino RM, Alabed HBR, Emiliani C, Caleo M, Cecchini M. Chronic lithium administration in a mouse model for Krabbe disease. JIMD Rep 2022;63:50-65. [PMID: 35028271 DOI: 10.1002/jmd2.12258] [Reference Citation Analysis]
6 Maurya S, Sarangi P, Jayandharan GR. Safety of Adeno-associated virus-based vector-mediated gene therapy-impact of vector dose. Cancer Gene Ther 2022. [PMID: 35027711 DOI: 10.1038/s41417-021-00413-6] [Reference Citation Analysis]
7 Heller GJ, Marshall MS, Issa Y, Marshall JN, Nguyen D, Rue E, Pathmasiri KC, Domowicz MS, van Breemen RB, Tai LM, Cologna SM, Crocker SJ, Givogri MI, Sands MS, Bongarzone ER. Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease. Mol Ther 2021;29:1883-902. [PMID: 33508430 DOI: 10.1016/j.ymthe.2021.01.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Levine SM, Tsau S. Substrate Reduction Therapy for Krabbe Disease: Exploring the Repurposing of the Antibiotic D-Cycloserine. Front Pediatr 2022;9:807973. [DOI: 10.3389/fped.2021.807973] [Reference Citation Analysis]
9 Antepowicz A, Habib O, Kirsebom F, Johansson C, Gill DR, Hyde SC. Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection. Sci Rep 2021;11:15694. [PMID: 34344952 DOI: 10.1038/s41598-021-95150-z] [Reference Citation Analysis]
10 Whisenant D, Lim K, Revêchon G, Yao H, Bergo MO, Machtel P, Kim JS, Eriksson M. Transient expression of an adenine base editor corrects the Hutchinson-Gilford progeria syndrome mutation and improves the skin phenotype in mice. Nat Commun 2022;13:3068. [PMID: 35654881 DOI: 10.1038/s41467-022-30800-y] [Reference Citation Analysis]
11 Nasir G, Chopra R, Elwood F, Ahmed SS. Krabbe Disease: Prospects of Finding a Cure Using AAV Gene Therapy. Front Med (Lausanne) 2021;8:760236. [PMID: 34869463 DOI: 10.3389/fmed.2021.760236] [Reference Citation Analysis]